Sutro Biopharma, Inc.

NasdaqGM:STRO Voorraadrapport

Marktkapitalisatie: US$266.4m

Sutro Biopharma Toekomstige groei

Future criteriumcontroles 2/6

De verwachting is dat Sutro Biopharma de winst en omzet met respectievelijk 2.8% en 24% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 12.1% per jaar.

Belangrijke informatie

2.8%

Groei van de winst

12.1%

Groei van de winst per aandeel

Biotechs winstgroei26.9%
Inkomstengroei24.0%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt20 Oct 2024

Recente toekomstige groei-updates

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Recent updates

Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Oct 11
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sep 23

There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Aug 24
There's No Escaping Sutro Biopharma, Inc.'s (NASDAQ:STRO) Muted Revenues Despite A 29% Share Price Rise

Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Aug 22
Brokers Are Upgrading Their Views On Sutro Biopharma, Inc. (NASDAQ:STRO) With These New Forecasts

Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

Aug 16
Analysts Are Upgrading Sutro Biopharma, Inc. (NASDAQ:STRO) After Its Latest Results

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

Jun 26
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet As Shares Tumble 28%

We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

May 31
We Think The Compensation For Sutro Biopharma, Inc.'s (NASDAQ:STRO) CEO Looks About Right

Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

Apr 02
Bearish: Analysts Just Cut Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue and EPS estimates

The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Mar 28
The Market Doesn't Like What It Sees From Sutro Biopharma, Inc.'s (NASDAQ:STRO) Revenues Yet

Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Dec 19
Sutro Biopharma, Inc.'s (NASDAQ:STRO) Price Is Right But Growth Is Lacking After Shares Rocket 43%

Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Aug 24
Is Sutro Biopharma (NASDAQ:STRO) Using Debt In A Risky Way?

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Feb 10
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Jan 12
An Intrinsic Calculation For Sutro Biopharma, Inc. (NASDAQ:STRO) Suggests It's 47% Undervalued

Sutro Biopharma: Partnership Progress Warrants Exposure

Aug 16

New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Aug 11
New Forecasts: Here's What Analysts Think The Future Holds For Sutro Biopharma, Inc. (NASDAQ:STRO)

Sutro Biopharma GAAP EPS of -$0.55, revenue of $28.1M

Aug 08

Sutro to get $10M payment from Merck after first patient dosed in collaboration trial

Jul 26

Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

May 02
Is Sutro Biopharma (NASDAQ:STRO) Using Too Much Debt?

Sutro; A Biotech To Watch With A Catalyst Rapidly Approaching

Dec 27

Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Dec 26
Is Sutro Biopharma (NASDAQ:STRO) A Risky Investment?

Sutro Biopharma initiated buy at H.C. Wainwright citing ADC candidates

Jun 18

Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

May 09
Industry Analysts Just Made A Sizeable Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) Revenue Forecasts

Winst- en omzetgroeiprognoses

NasdaqGM:STRO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202666-290-177-2569
12/31/202558-280-219-23811
12/31/202469-228-187-17111
6/30/2024169-124-78-75N/A
3/31/2024154-115-119-115N/A
12/31/2023154-107-116-112N/A
9/30/202349-172-156-150N/A
6/30/202357-143-57-50N/A
3/31/202375-130-29-22N/A
12/31/202268-119-44N/A
9/30/202270-123-16N/A
6/30/202253-134-96-84N/A
3/31/202253-114-101-87N/A
12/31/202162-106-97-82N/A
9/30/202160-127-93-79N/A
6/30/202169-79-85-72N/A
3/31/202150-43-88-79N/A
12/31/202043-32-75-68N/A
9/30/20204613-70-62N/A
6/30/202040-17-66-61N/A
3/31/202041-61-68-64N/A
12/31/201943-56-69-65N/A
9/30/201951-42-60-58N/A
6/30/201946-4046N/A
3/31/201941-3868N/A
12/31/201838-351113N/A
9/30/201823-491214N/A
6/30/201833-40-38-36N/A
3/31/201842-30N/A-37N/A
12/31/201752-20N/A-37N/A
12/31/201660N/AN/A-13N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat STRO de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van STRO ( 24% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van STRO ( 24% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van STRO naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven